[{"orgOrder":0,"company":"Eisai Inc","sponsor":"PRISM BioLab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"E7386","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ PRISM BioLab","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ PRISM BioLab"}]

Find Clinical Drug Pipeline Developments & Deals for E7386

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.

                          Brand Name : E7386

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 01, 2021

                          Lead Product(s) : E7386,Lenvatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : PRISM BioLab

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank